Navigation Links
Hurel Corporation Appoints Leading Pharmaceutical Executive and Toxicologist Dr. James S. MacDonald to Board of Directors
Date:5/21/2013

NORTH BRUNSWICK, N.J., May 21, 2013 /PRNewswire/ -- Hurel Corporation ("Hurel"), a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms, today announced the appointment of James S. MacDonald , PhD, DABT to the Company's Board of Directors. Dr. MacDonald is the former Executive Vice President of Preclinical Development of the Schering-Plough Research Institute ("SPRI"), which was the pharmaceutical development arm of Schering Corporation prior to its acquisition by Merck & Co. in 2009.

Over a career that has spanned more than three decades, Dr. MacDonald has brought hundreds of drug candidates into development, over thirty of which have become globally registered, major drugs, including Vasotec®, Zocor®, Primaxin®, Clinoril®, Prilosec®, Fosamax®, Clarinex®, Nasonex®, Vytorin®, and Victrelis®, among others. Dr. MacDonald joined SPRI in 1994 as Senior Vice President, Drug Safety and Metabolism, and, over the next 14 years up until the time of the Merck acquisition, he played a leading role in building one of the most distinguished and effective drug development organizations in the world. As co-chairman of SPRI's Early Development Committee, he directed the movement of drug candidates from discovery research into and through the development process. Previously, Dr. MacDonald held positions of increasing responsibility at Merck, including Executive Director of Toxicology. He received his Ph.D. in toxicology in 1975 from the University of Cincinnati and completed a post-doctoral fellowship at Vanderbilt University. He became a diplomate of the American Board of Toxicology in 1980.

" Jim MacDonald 's track record of getting pharmaceuticals approved by FDA and onto the market speaks for itself," said Robert Freedman , Hµrel's Chairman and CEO. "Hµrel is privileged to benefit from Jim's extraordinary wisdom and experience, both as a scientist and as a drug development executive. His guidance will be invaluable. We welcome Jim to the Board as a colleague and friend."

About Hurel
Hurel Corporation, based in North Brunswick, NJ and Beverly Hills, CA, is a world-leading provider of advanced artificial tissue constructs and microfluidic cell-based assay platforms which are used by biotech and pharmaceutical research organizations in pre-clinical drug development, as well as in the toxicological testing of industrial materials and consumer products. The Company recently announced a $9.2 million Series "A" equity private placement led by Spring Mountain Capital, of New York.  Funds from the transaction will provide working capital to support the current commercial launch of the Company's products and the continuing research and development of its technologies and future products.


'/>"/>
SOURCE Hurel Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Hurel Receives $9.2 Million Series A Funding From Spring Mountain Capital
2. TNI BioTech, Inc. Corporations CEO Issues Letter to Shareholders Discussing Recent Events
3. X-Change Corporation Launches Upgraded Version of Phytiva Website, As Company Targets Distribution of Phytiva Product Line in United States and Worldwide, Extracts and New Products in Europe
4. Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan
5. Healthcare Corporation of America Sets Date for Release of its First-Quarter Results and Conference Call
6. Comprehensive Care Corporation Announces Pharmacy Savings Management Agreement With Utica City School District
7. Omeros Corporation Reports First Quarter 2013 Financial Results
8. Heska Corporation to Present at the 14th Annual B. Riley & Co. Investor Conference
9. Sigma-Aldrich Corporation Declares $0.215 Per Share Quarterly Dividend
10. Luminex Corporation To Present At Upcoming Investment Conferences
11. Celladon Corporation is a Finalist for the 2013 Red Herring Top 100 North America Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016  The blood testing market ... dollars, according to Kalorama Information and The Freedonia Group ... and nucleic acid testing.  The healthcare research firm said ... in developing blood collection stations and in improving testing ... Kalorama Information,s report, Blood Testing Market in ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... flexibility in repaying their loans, more information about their loan terms and accounts, ... outstanding student loan debt, including federal and private loans, has reached $1.3 trillion, ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... Kansas City, Missouri (PRWEB) , ... April 29, 2016 , ... ... Unlike traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes ... less strain on their wrists and hands when using the crutches than with other ...
(Date:4/29/2016)... ... 29, 2016 , ... Melanoma is the deadliest type of skin cancer. Although only about 1 ... skin cancer deaths. More than 10,000 people are expected to die of melanoma this year. ... is the one of the most commonly diagnosed cancers in young women. A recent breakthrough ...
(Date:4/29/2016)... ... ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a leading ... specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , A ... safety device secured by nasal surgeons onto the floor of the nasal passages, at ...
Breaking Medicine News(10 mins):